<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lyell Immunopharma Inc — News on 6ix</title>
<link>https://6ix.com/company/lyell-immunopharma-inc</link>
<description>Latest news and press releases for Lyell Immunopharma Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 07 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lyell-immunopharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683594de78dffbe2df103e56.webp</url>
<title>Lyell Immunopharma Inc</title>
<link>https://6ix.com/company/lyell-immunopharma-inc</link>
</image>
<item>
<title>Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-participation-in-25th-annual-needham-virtual-healthcare-conference</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of</description>
</item>
<item>
<title>Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-q4-and-full-year-2025-business-and-financial-results</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Finan</description>
</item>
<item>
<title>Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-closing-of-additional-dollar50-million-tranche-of-equity-private-placement-and-appointment-of-smital-shah-as-chief-financial-and-business-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-closing-of-additional-dollar50-million-tranche-of-equity-private-placement-and-appointment-of-smital-shah-as-chief-financial-and-business-officer-1</guid>
<pubDate>Mon, 09 Mar 2026 12:00:00 GMT</pubDate>
<description>Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale</description>
</item>
<item>
<title>Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer </title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-closing-of-additional-dollar50-million-tranche-of-equity-private-placement-and-appointment-of-smital-shah-as-chief-financial-and-business-officer</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-closing-of-additional-dollar50-million-tranche-of-equity-private-placement-and-appointment-of-smital-shah-as-chief-financial-and-business-officer</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital</description>
</item>
<item>
<title>Lyell Immunopharma Announces Participation in March Investor Conferences</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-participation-in-march-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-participation-in-march-investor-conferences</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of</description>
</item>
<item>
<title>Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-initiation-patient-123000058</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-initiation-patient-123000058</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>PiNACLE – H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second-line settingThe pivotal single-arm trial, PiNACLE, evaluating ronde-cel in the third- or later-line setting is ongoing with BLA submission expected in 2027Site activation for both PiNACLE – H2H and PiNACLE are underway in the United States, Canada and Aust</description>
</item>
<item>
<title>Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-presents-clinical-data-213000869</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-presents-clinical-data-213000869</guid>
<pubDate>Sun, 07 Dec 2025 21:30:00 GMT</pubDate>
<description>93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell lymphoma in the 3L+ setting83% overall response and 61% complete response rates in cohort comprised predominantly of patients with primary refractory large B-cell lymphoma in the 2L settingManageable safety profile appropriate for outpatient administration; no high-grade CRS and ≤ 5% of patients with Grade ≥ 3 ICANS following dexamethasone prophylaxisLyell managem</description>
</item>
<item>
<title>Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-210500689</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-210500689</guid>
<pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
<description>Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer in an ongoing U.S. Phase 1 clinical trialReceived RMAT designation from the U.S. FDA for ronde-cel for the treatment of patients with relapsed or refractory LBCL receiving treatment in the second-</description>
</item>
<item>
<title>Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 </title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-third-quarter-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-and-financial-results-for-the-third-quarter-2025</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong</description>
</item>
<item>
<title>Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-acquires-exclusive-global-123000581</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-acquires-exclusive-global-123000581</guid>
<pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
<description>LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killingLyell management will host an investor webcast at 8:30 AM ET today SOUTH SAN FRANCISCO, Calif.,</description>
</item>
<item>
<title>Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-announces-two-oral-presentations-140000165</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-announces-two-oral-presentations-140000165</guid>
<pubDate>Mon, 03 Nov 2025 14:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th America</description>
</item>
<item>
<title>Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-initiation-phase-120000828</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-initiation-phase-120000828</guid>
<pubDate>Wed, 03 Sep 2025 12:00:00 GMT</pubDate>
<description>PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lyell’s next-generation, dual-targeting CD19/CD20 CAR T-cell therapy designed to deliver improved complete response rates and longer duration of responses over currently approved CD19 CAR T-cell therapiesSteering Committee of distinguished lymphoma expe</description>
</item>
<item>
<title>Lyell Immunopharma Announces Participation in September Investor Conferences</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-participation-september-200500095</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-participation-september-200500095</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the following investor conferences: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8th at 9:15 am Eastern TimeH.C. Wainwright 27th</description>
</item>
<item>
<title>Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-200500751</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-200500751</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>Presented positive new clinical data demonstrating high rates of durable complete responses from the Phase 1/2 trial of LYL314 for the treatment of aggressive large B-cell lymphomaInitiated the PiNACLE pivotal trial of LYL314 in patients with large B-cell lymphoma receiving treatment in the third‑ or later-line (3L+) setting; remain on track to initiate a pivotal trial in the second-line (2L) setting by early 2026Entered into a securities purchase agreement for a private placement for gross proc</description>
</item>
<item>
<title>Lyell Immunopharma Announces up to $100 Million Equity Private Placement</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-100-million-120000863</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-100-million-120000863</guid>
<pubDate>Fri, 25 Jul 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement with certain institutional and other accredited investors, for gross proceeds of up to approximately $100 million. The initial closing of approximately $50 million of common stock at a price of $13.32</description>
</item>
<item>
<title>Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-participate-h-c-210000653</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-participate-h-c-210000653</guid>
<pubDate>Mon, 23 Jun 2025 21:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwright “HCW@Home” Series taking place virtually on Wednesday, June 25, 2025, at 12:00 PM ET. The discussion will highlight the positive new clinical data recently presented in an oral session at the Interna</description>
</item>
<item>
<title>Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-positive-clinical-103000000</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-announces-positive-clinical-103000000</guid>
<pubDate>Tue, 17 Jun 2025 10:30:00 GMT</pubDate>
<description>LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25)71% of patients with complete response remained in complete response at ≥ 6 monthsManageable safety profile appropriate for outpatient administration with no Grade ≥ 3 cytokine release syndrome and low rates of Grade ≥ 3 ICANS with rapid resolutionPivotal single-arm PiNACLE trial is underway in CAR T-naïve patients with</description>
</item>
<item>
<title>Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-strengthens-clinical-commercial-200500112</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-strengthens-clinical-commercial-200500112</guid>
<pubDate>Mon, 09 Jun 2025 20:05:00 GMT</pubDate>
<description>Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announce</description>
</item>
<item>
<title>Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-participate-goldman-sachs-200500392</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-participate-goldman-sachs-200500392</guid>
<pubDate>Wed, 04 Jun 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Compan</description>
</item>
<item>
<title>Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025</title>
<link>https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-200500841</link>
<guid isPermaLink="true">https://6ix.com/company/lyell-immunopharma-inc/news/lyell-immunopharma-reports-business-highlights-200500841</guid>
<pubDate>Tue, 13 May 2025 20:05:00 GMT</pubDate>
<description>Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma.Received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for LYL314 for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma in</description>
</item>
</channel>
</rss>